Novartis beats forecasts, despite generic and currency hits
05:53 EDT 19 Jul 2012 | thePharmaLetter
Second-quarter 2012 group net sales at Swiss drug major Novartis (NOVN: VX) came in at of $14.3 billion, a rise of 1% at constant currency, with growth in recently-launched products more than offsetting loss due to patent expiry on the firm's once bl..
Original Article: Novartis beats forecasts, despite generic and currency hits
More From BioPortfolio on "Novartis beats forecasts, despite generic and currency hits"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
